ScholarLens Back to search
2012•HAL (Le Centre pour la Communication Scientifique Directe)Requires access

O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and Low MGMT-Encoded Protein Expression as Prognostic Markers in Glioblastoma Patients Treated with Biodegradable Carmustine Wafer Implants after Initial Surgery Followed by Radiotherapy with Concomitant and Adjuvant Temozolomide

Js Guillamo, Guénaëlle Levallet, A. Dugué, A Vital, Md Diebold, P Menei, Philippe Colin, P. Peruzzy, E. Emery, Myriam Bernaudin, Françoise Chapon, E Lechapt-Zalcman

Open publisher page 8 citations

Abstract

International audience

About this research paper

What this paper is about

International audience

Why it matters

OpenAlex reports 8 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

International audience

Key concepts: Methyltransferase, Carmustine, O-6-methylguanine-DNA methyltransferase, Cancer research, Temozolomide, Methylation, Glioblastoma, Radiation therapy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and Low MGMT-Encoded Protein Expression as Prognostic Markers in Glioblastoma Patients Treated with Biodegradable Carmustine Wafer Implants after Initial Surgery Followed by Radiotherapy with Concomitant and Adjuvant Temozolomide — Research Paper | ScholarLens